news

as the cornerstone of national health and national security, the pharmaceutical industry is a key engine for advancing the "healthy china 2030" blueprint. high-quality development led by scientific and technological innovation is the only way for this industry to transform and upgrade. as an innovation pioneer in the industry, eddingpharm has recently made new achievements in its high-quality development journey and has been praised by the government and the industry.

in june 2024, vispas®, which was authorized and independently developed by eddingpharm in china, successfully obtained formal approval from the national medical products administration. its second indication - reducing the risk of cardiovascular events - marks a new milestone in china's cardiovascular treatment field.

the implementation of this innovative achievement of edding pharmaceuticals is another fruitful result of edding pharmaceuticals' long-term commitment to the dual-wheel drive strategy of innovation and internationalization. "we are well aware that in the field of medicine, only continuous innovation can meet the growing health needs of patients and promote the continuous progress of the industry." mr. ni xin, chairman and ceo of edding pharmaceuticals, said in an interview, "the approval of vispas is not only a recognition of our r&d strength, but also the best proof of edding pharmaceuticals' adherence to the innovation-driven development strategy."

in recent years, eddingpharm has continued to increase its r&d investment and built a full life cycle r&d system covering new drug discovery, preclinical research, clinical trials and post-marketing. eddingpharm is a local pharmaceutical company with both domestic and international supply chain management capabilities. it has brought together high-quality life science and leading medical resources from around the world to form a strong r&d innovation network. through in-depth cooperation with top international scientific research institutions and companies, eddingpharm has continuously introduced and absorbed the world's advanced r&d technology and management experience, promoting the continuous upgrading of its own technology platform and the rapid expansion of its r&d pipeline.

so far, eddingpharm has had a number of innovative drugs approved for marketing in china, covering multiple therapeutic areas such as cardiovascular and respiratory diseases, forming a relatively complete product matrix. at the same time, the company has dozens of independent innovation projects in the clinical development stage, and hundreds of clinical trials are being carried out in an orderly manner around the world, laying a solid foundation for the sustainable development of eddingpharm in the future.

with the continuous emergence of innovative r&d results and the in-depth promotion of internationalization strategy, eddingpharm is accelerating towards a new stage of high-quality development. "we firmly believe that innovation is the inexhaustible driving force for corporate development." mr. ni xin emphasized, "eddingpharm will continue to uphold the concept of 'patient-centered, innovation-driven development', continue to increase r&d investment, expand r&d fields, and strive to provide more safe, effective and affordable innovative drugs for chinese and global patients."